• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

PharmaJet wins NIH grant to evaluate needle-free delivery of HPV immunization

November 29, 2022 By Sean Whooley

PharmaJet Tropis needle-free intradermal injection system
The Tropis needle-free injection system. [Image from PharmaJet]
PharmaJet announced today that it received a grant worth $800,000-plus from the NIH to evaluate its needle-free injection system.

Golden, Colorado-based PharmaJet picked up a Phase II grant from the NIH (National Institutes of Health). It allows the company to evaluate the immunogenicity of the intradermal administration of human papillomavirus virus (HPV) vaccine. The study compares PharmaJet’s Tropis intradermal, needle-free injection system against traditional needle and syringe intramuscular administration.

According to a news release, the study will be performed in collaboration with Padjadjaran University (UNPAD) in Indonesia. PharmaJet expects the study to recruit approximately 900 girls aged nine to 14 in early 2023. This follows PharmaJet’s preliminary studies evaluating intradermal delivery for HPV vaccines.

“We are pleased to receive this grant from the NIH to evaluate the feasibility of needle-free intradermal vaccine delivery for HPV,” said Erin Spiegel, VP of clinical and regulatory affairs for PharmaJet. “Intradermal administration of vaccines can provide benefits for low resource settings including lower costs, increased coverage, and increased acceptability.”

PharmaJet said intradermal administration represents a safe, effective, immunogenic option for polio vaccine delivery. Healthcare workers and patients prefer using the Tropis needle-free approach in polio vaccine delivery, too, the company said.

Other uses for PharmaJet’s needle-free vaccine delivery include COVID-19 vaccines and other RNA and DNA candidates. Earlier this year, the company announced study data demonstrating increased immunogenicity when using the needle-free delivery system.

Filed Under: Business/Financial News, Clinical Trials, Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals, Preclinical Trials Tagged With: National Institutes of Health, PharmaJet

IN CASE YOU MISSED IT

  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • Sequel Med Tech expects full twiist launch in the fall
  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS